TLX Battle Card: Risk, Performance & Setup

Health

Performance

9.1

Risk

Sell

Buy

Curious about the Scores? Learn more.

Telix Pharmaceuticals Limited stock rating and score history

All changes in ratings, performance and outlook tracked over time.

14.12.2025

Rock bottom. The fall’s complete, stability nowhere to be found.

20.08.2025

Pulse detected. Still fragile, but stabilizing.

Telix Pharmaceuticals Limited stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Telix Pharmaceuticals Limited do? Business model and key facts

Get the full picture of Telix Pharmaceuticals Limited: what it builds, where it operates, and how it makes money.

Telix Pharmaceuticals Limited Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): N/A

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.